Targeting the molecular pathways that drive neutrophil plasticity in NASH, such as CXCR2 and RIPK3 signaling, may offer novel therapeutic opportunities for the treatment of this prevalent and progressive metabolic disorder. This evidence concerns the gene RIPK3 and metabolic dysfunction-associated steatohepatitis.